Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

Intratumoral talimogene laherparepvec injection with concurrent preoperative radiation in patients with locally advanced soft-tissue sarcoma of the trunk and extremities: phase IB/II trial.

Varun Monga | Benjamin J Miller | Munir Tanas | Sarag Boukhar | Bryan Allen | Carryn Anderson | Laura Stephens | Stacey Hartwig | Steven Varga | Jon Houtman | Lei Wang | Weizhou Zhang | Omar Jaber | Jon Thomason | David Kuehn | Maheen Rajput | Catherine Metz | K D Zamba | Sarah Mott | Chinemerem Abanonu | Sudershan Bhatia | Mohammed Milhem
Journal for immunotherapy of cancer | 2021

Soft-tissue sarcomas (STS) in the extremities and trunk treated with standard-of-care preoperative external beam radiation therapy (EBRT) followed by surgical resection are associated with local and distant relapses. In preclinical studies, oncolytic virotherapy in sarcoma has demonstrated antitumor effects via direct intratumoral oncolysis and cytotoxic T-cell-mediated immune responses. Talimogene laherparepvec (TVEC) is a replication-competent, immune-enhanced, oncolytic herpes simplex virus type 1 engineered for intratumoral injection; it has been approved by the FDA for the treatment of locally advanced and metastatic melanoma.

Pubmed ID: 34330766

Research resources used in this publication

None found

Additional research tools detected in this publication

Antibodies used in this publication

None found

Associated grants

  • Agency: NCI NIH HHS, United States
    Id: P30 CA086862
  • Agency: NCI NIH HHS, United States
    Id: R01 CA200673
  • Agency: NCI NIH HHS, United States
    Id: R01 CA203834
  • Agency: NCI NIH HHS, United States
    Id: R01 CA260239

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


Dako (tool)

RRID:SCR_013530

An Antibody supplier; Dako was purchased by Agilent in 2012 and several years later the websites began to reflect the Dako products as part of the Agilent catalog.

View all literature mentions